A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma

JP Laubach; JJ Moslehi; SA Francis; JF San Miguel; Pieter Sonneveld; RZ Orlowski; P Moreau; L Rosinol; EA Faber; P Voorhees; MV Mateos; L Marquez; HB Feng; A Desai; HV de Velde; J Elliott; HL Shi; E Dow; N Jobanputra; DL Esseltine; L Niculescu; KC Anderson; S Lonial; PG Richardson

doi:10.1111/bjh.14708

A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma

JP Laubach, JJ Moslehi, SA Francis, JF San Miguel, Pieter Sonneveld, RZ Orlowski, P Moreau, L Rosinol, EA Faber, P Voorhees, MV Mateos, L Marquez, HB Feng, A Desai, HV de Velde, J Elliott, HL Shi, E Dow, N Jobanputra, DL EsseltineL Niculescu, KC Anderson, S Lonial, PG Richardson

Hematology

Research output: Contribution to journal › Article › Academic › peer-review

47 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	547-560
Number of pages	14
Journal	British Journal of Haematology
Volume	178
Issue number	4
DOIs	https://doi.org/10.1111/bjh.14708
Publication status	Published - 2017

Research programs

EMC OR-01

Access to Document

10.1111/bjh.14708

http://hdl.handle.net/1765/108405

Cite this

Laubach, JP., Moslehi, JJ., Francis, SA., San Miguel, JF., Sonneveld, P., Orlowski, RZ., Moreau, P., Rosinol, L., Faber, EA., Voorhees, P., Mateos, MV., Marquez, L., Feng, HB., Desai, A., de Velde, HV., Elliott, J., Shi, HL., Dow, E., Jobanputra, N., ... Richardson, PG. (2017). A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. British Journal of Haematology, 178(4), 547-560. https://doi.org/10.1111/bjh.14708

@article{9a72741444cd426fa8572cd9d1b25872,

title = "A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma",

author = "JP Laubach and JJ Moslehi and SA Francis and \{San Miguel\}, JF and Pieter Sonneveld and RZ Orlowski and P Moreau and L Rosinol and EA Faber and P Voorhees and MV Mateos and L Marquez and HB Feng and A Desai and \{de Velde\}, HV and J Elliott and HL Shi and E Dow and N Jobanputra and DL Esseltine and L Niculescu and KC Anderson and S Lonial and PG Richardson",

year = "2017",

doi = "10.1111/bjh.14708",

language = "Undefined/Unknown",

volume = "178",

pages = "547--560",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley \& Sons Inc.",

number = "4",

}

Laubach, JP, Moslehi, JJ, Francis, SA, San Miguel, JF, Sonneveld, P, Orlowski, RZ, Moreau, P, Rosinol, L, Faber, EA, Voorhees, P, Mateos, MV, Marquez, L, Feng, HB, Desai, A, de Velde, HV, Elliott, J, Shi, HL, Dow, E, Jobanputra, N, Esseltine, DL, Niculescu, L, Anderson, KC, Lonial, S & Richardson, PG 2017, 'A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma', British Journal of Haematology, vol. 178, no. 4, pp. 547-560. https://doi.org/10.1111/bjh.14708

A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. / Laubach, JP; Moslehi, JJ; Francis, SA et al.
In: British Journal of Haematology, Vol. 178, No. 4, 2017, p. 547-560.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma

AU - Laubach, JP

AU - Moslehi, JJ

AU - Francis, SA

AU - San Miguel, JF

AU - Sonneveld, Pieter

AU - Orlowski, RZ

AU - Moreau, P

AU - Rosinol, L

AU - Faber, EA

AU - Voorhees, P

AU - Mateos, MV

AU - Marquez, L

AU - Feng, HB

AU - Desai, A

AU - de Velde, HV

AU - Elliott, J

AU - Shi, HL

AU - Dow, E

AU - Jobanputra, N

AU - Esseltine, DL

AU - Niculescu, L

AU - Anderson, KC

AU - Lonial, S

AU - Richardson, PG

PY - 2017

Y1 - 2017

U2 - 10.1111/bjh.14708

DO - 10.1111/bjh.14708

M3 - Article

C2 - 28466536

SN - 0007-1048

VL - 178

SP - 547

EP - 560

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 4

ER -

Laubach JP, Moslehi JJ, Francis SA, San Miguel JF, Sonneveld P, Orlowski RZ et al. A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. British Journal of Haematology. 2017;178(4):547-560. doi: 10.1111/bjh.14708